Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 228

The DOI matches its Crossref record.

Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience

Raverot, Gérald, Sturm, Nathalie, de Fraipont, Florence, Muller, Marie, Salenave, Sylvie, Caron, Philippe, Chabre, Olivier, Chanson, Philippe, Cortet-Rudelli, Christine, Assaker, Richard, Dufour, Henry, Gaillard, Stephan, François, Patrick, Jouanneau, Emmanuel, Passagia, Jean-Guy, Bernier, Michèle, Cornélius, Aurélie, Figarella-Branger, Dominique, Trouillas, Jacqueline, Borson-Chazot, Françoise, Brue, Thierry · 2010 · The Journal of Clinical Endocrinology & Metabolism

Abstract

CONTEXT: To date only 18 patients with aggressive pituitary tumors or carcinomas treated with temozolomide have been reported. Increased expression of O6-methylguanine-DNA-methyltranferase (MGMT) has been suggested to predict resistance to temozolomide. OBJECTIVES: The objective of the study was to describe the antitumoral efficacy and toxicity of temozolomide in patients with aggressive pituitary tumors or carcinomas and evaluate the possible prognostic value of MGMT promoter methylation and protein expression. PATIENTS: Eight patients, five with pituitary carcinomas (three prolactin (PRL) and two ACTH) and three with aggressive pituitary tumors (one PRL and two ACTH), all treated with temozolomide administered orally for four to 24 cycles, were included in our French multicenter study. DESIGN: MGMT expression was assessed by immunohistochemistry and MGMT promoter methylation by pyrosequencing. RESULTS: Three of the eight patients (two ACTH adenomas and one PRL carcinoma) responded to temozolomide as demonstrated by significant tumor shrinkage and reduced hormone secretion. Three cycles of temozolomide were sufficient to identify treatment-responsive patients. Additional cycles did not improve treatment efficacy in those not responding, even when associated with carboplatin and vepeside. MGMT expression did not predict tumoral response to temozolomide because it was positive in one responder and negative in two nonresponders. Similarly, MGMT promoter methylation (three of seven tumors) did not predict clinical response. Toxicity remained mild in all patients. CONCLUSION: Temozolomide treatment may be an effective option for some aggressive pituitary tumors or carcinomas. Response to a trial of three cycles of treatment seems sufficient to identify responders and more reliable than patient MGMT status.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2010-0644

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 228

Metadata

Authors
Raverot, G., Sturm, N., de Fraipont, F., Muller, M., Salenave, S., Caron, P., Chabre, O., Chanson, P., Cortet-Rudelli, C., Assaker, R., Dufour, H., Gaillard, S., François, P., Jouanneau, E., Passagia, J.-G., Bernier, M., Cornélius, A., Figarella-Branger, D., Trouillas, J., Borson-Chazot, F., & Brue, T.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2010-10
Volume
95
Issue
10
Pages
4592-4599
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W1965579078
Cited by
228
References
0
FWCI
15.85
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience. https://app.cochat.ai/papers/10.1210/jc.2010-0644
The paper
Raverot, G., Sturm, N., de Fraipont, F., Muller, M., Salenave, S., Caron, P., Chabre, O., Chanson, P., Cortet-Rudelli, C., Assaker, R., Dufour, H., Gaillard, S., François, P., Jouanneau, E., Passagia, J.-G., Bernier, M., Cornélius, A., Figarella-Branger, D., Trouillas, J., . . . Brue, T. (2010). Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2010-0644

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.